hotspot -WSS

hotspot

author：comprehensive 2025-09-30 22:04:12 - browse：965

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Scientists boost immune system in aging mice by making it youthful

WSS

Eisai exec who led development of Alzheimer’s drug to retire

Biden’s NIH nominee is languishing in Congress

Biden’s NIH nominee is languishing in Congress

Abortion pill case raises question: who can sue the FDA?

The aspartame in Diet Coke probably isn’t giving you cancer

Readout Newsletter: Merck, Vertex, and Viking updates

explore

hotspot

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biden declares emergency in flood

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Merck, Vertex, and Viking updates

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

New air purifier tech could be key to improving indoor air quality

Biden’s NIH nominee is languishing in Congress

knowledge

The Readout: Lenmeldy, GLP

The aspartame in Diet Coke probably isn’t giving you cancer

Vertex Pharmaceuticals may move headquarters in Boston

Recent heat wave in the Mediterranean caused by climate change: Study

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Eisai exec who led development of Alzheimer’s drug to retire

explore

Wikipedia

knowledge

explore